Ginkgo Bioworks Holdings Inc. Class A Company Profile
NYSE: DNAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ginkgo Bioworks at a glance
Ginkgo Bioworks Holdings Inc. Class A (NYSE: DNA) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Boston, MA. Ginkgo Bioworks is led by Dr. Jason Kelly Ph.D. and employs about 485 people. The company's shares have traded publicly since 2021.
At a market capitalization of $483.5 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001830214, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Ginkgo Bioworks do?
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Business description based on the company's public filings.
Company information
- Legal name
- Ginkgo Bioworks Holdings Inc. Class A
- Ticker
- NYSE: DNA
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Jason Kelly Ph.D.
- Employees
- 485
- Headquarters
- 27 Drydock Avenue, Boston, MA, United States
- Phone
- 877 422 5362
- Website
- ginkgo.bio
- IPO year
- 2021
- Market cap
- $483.54M
- SEC CIK
- 0001830214
- Latest annual report
- 10-K · Feb 26, 2026
Companies similar to Ginkgo Bioworks
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SANASana Biotechnology Inc. | 1.59 | -8.62% | $476.42M | vs DNA |
| VALNValneva SE ADR | 5.16 | -3.82% | $490.86M | vs DNA |
| RGNXREGENXBIO Inc. | 7.16 | -0.28% | $473.44M | vs DNA |
| FENCFennec Pharmaceuticals Inc. | 13.09 | -2.68% | $462.14M | vs DNA |
| ETRAElectra Therapeutics Inc. | 8.11 | -9.28% | $509.85M | vs DNA |
| IRLAIRulya Therapeutics Inc. | 39.88 | -0.15% | $432.36M | vs DNA |
| PROKProKidney Corp. Class A | 1.04 | -1.89% | $415.21M | vs DNA |
| TECXTectonic Therapeutic Inc. | 20.73 | -1.47% | $405.26M | vs DNA |